Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2016 August;82(8) > Minerva Anestesiologica 2016 August;82(8):884-94

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

EXPERTS’ OPINIONS   Freefree

Minerva Anestesiologica 2016 August;82(8):884-94

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Bleeding management in patients with new oral anticoagulants

Maria VARGAS 1, Annachiara MARRA 1, Antonietta PERRONE 2, Giuseppe SERVILLO 1

1 Unit of Anesthesia and Intensive Care, Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples “Federico II”, Naples, Italy; 2 Unit of Clinical Engineering, Department of Clinical Engineering, University of Naples “Federico II”, Naples, Italy


PDF


New oral anticoagulants (NOACs) have been developed in recent years and are increasingly used in clinical practice. Dabigatran is a direct thrombin (factor II) inhibitor while rivaroxaban, apixaban and edoxaban are direct inhibitors of factor Xa. The European Medicines Agency (EMA) currently approves these NOACs for different clinical uses. NOACs do not require routine monitoring of coagulation although an assessment of anticoagulation activity in these patients may be required in different conditions. NOACs show a similar or lower incidence of bleeding compared with conventional therapies in phase III trials. In case of bleeding, non-specific reversal strategies are available while specific reversal agents are the subject of ongoing trials. The role of this review is to summarize the current knowledge on NOCAs focusing on bleeding management in the perioperative period.

top of page